Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

The Daily Look, Mid-week view, Wednesday - 4/13/11

The regenerative medicine/stem cell universe stocks started out very strong but, bounded downward mid to late day, Wednesday (4/13/11). 

The NASDAQ rose 16.73 (0.61%) to 2761.52. On Wednesday, 4/13/11, larger volume heightened depreciation … (Yesterday = Y)

Advancing companies (9)

  • Athersys (NASDAQ:ATHX) up $0.04 (1.53%) to $2.96 (Y $2.92);
  • Aastrom (ASTM) up $0.04 (1.59%) to $2.56 (Y $2.52);
  • Bioheart (BHRT.OB)  up $0.01 (5.56%) to $0.19 (Y $0.18);
  • International Stem Cell (OTCQB:ISCO) up $0.06 (4.84%) to $1.30 (Y $1.24);
  • ImmunoCellar Therapeutics (NYSEMKT:IMUC) up $0.02 (0.84%) to $2.39 (Y $2.37);
  • Pluristem (NASDAQ:PSTI) up $0.16 (5.42%) to $3.11 (Y $2.58);
  • NeoStem (AMEX: NBS) up $0.01 (0.51%) at $1.96 (Y $1.95);
  • ThermoGenesis (NASDAQ:KOOL) up 0.03 (1.35%) to $2.25 (Y $2.22); and
  • StemCells (STEM) up $0.01 (1.30%) to $0.78 (Y $0.77);

Trading down companies (10):

  • Advanced Cell (OTC: ACTC) down $0.002 (-0.83%) to $0.19 (Y $0.19);
  • BioMimetic (NASDAQ:BMTI) down -$0.05 (-0.37%) to $13.35 (Y $13.40);
  • BioTime (AMEX: BTX) down -$0.18 (-2.38%) to $7.39 (Y $7.57);
  • Brainstorm (NASDAQ:BCLI) down -$0.003 (-1.02%) at $0.292 (Y $0.39)
  • Cytori (NASDAQ:CYTX) down -$0.21 (-2.60%) to $7.88 (Y $8.09);  
  • Geron (NASDAQ:GERN) down -$0.03 (-0.61%) to $4.90 (Y $4.93);
  • Neuralstem (AMEX:CUR) down -$0.03 (-1.66%) to $1.78 (Y $1.81);  
  • Osiris (NASDAQ:OSIR) down -$ 0.27 (-4.07%) to $6.36 (Y $6.63);
  • ReNeuron Group (RENE.L) down -$0.10 (-1.65%) to $5.66 (Y $5.76); and
  • Tengion (TNGN) down -$0.06 (-2.29%) to $2.56 (Y $2.62);

Flat (1):

  • Opexa (OPXA) flat at $1.86 (Y $1.86)

The Bottom Line:  US equities finished slightly higher in choppy trading on 4/13/11. There did not seem to be anything specific behind depreciating actions. Despite some semblance of a bounce in risk appetite, the lack of meaningful direction seemed to fit with the heightened uncertainty surrounding a number of high-profile thematic drivers for stocks, particularly the momentum on both the earnings and economic calendars. The ongoing budget deficit reduction battle in Washington and accompanying implications for the debt ceiling seemed to exacerbate some of the noise in the market today, as did the mixed takeaways on the regulatory front. The biggest daily percentage (%) winners of the regenerative medicine universe were Pluristem (PSTI) up $0.16 (5.42%) to $3.11; International Stem Cell (OTCQB:ISCO) up $0.06 (4.84%) to $1.30; followed by Athersys (ATHX) up $0.04 (1.53%) to $2.96 and Aastrom (ASTM) up $0.04 (1.59%) to $2.56. News today, reflected ThermoGenesis’ (KOOL) Res-Q registration in India, NeoStem’s (AMEX: NBS) PCT subsidiary receiving manufacturing accreditation and Pluristem’s (PSTI) PI 3 and 6 month CLI trial follow-up. Overall, we are not very happy when ups (9) versus downs (10) dominate our universe after the morning started out … so strong.